Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials

• James F. Curtin,

  Affiliations Department of Biomedical Sciences, Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America, Department of Medicine, The Brain Research Institute, and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America, Department of Molecular and Medical Pharmacology, The Brain Research Institute, and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Marianela Candolfi,

  Affiliations Department of Biomedical Sciences, Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America, Department of Medicine, The Brain Research Institute, and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America, Department of Molecular and Medical Pharmacology, The Brain Research Institute, and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Tamer M. Fakhouri,

  Affiliation Department of Biomedical Sciences, Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America

  ⨯
• Chunyan Liu,

  Affiliations Department of Biomedical Sciences, Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America, Department of Medicine, The Brain Research Institute, and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America, Department of Molecular and Medical Pharmacology, The Brain Research Institute, and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Anderson Alden,

  Affiliation Department of Biomedical Sciences, Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America

  ⨯
• Matthew Edwards,

  Affiliation Department of Biomedical Sciences, Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America

  ⨯
• Pedro R. Lowenstein,

  Affiliations Department of Biomedical Sciences, Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America, Department of Medicine, The Brain Research Institute, and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America, Department of Molecular and Medical Pharmacology, The Brain Research Institute, and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Maria G. Castro

  *To whom correspondence should be addressed. E-mail: castromg@cshs.org

  Affiliations Department of Biomedical Sciences, Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America, Department of Medicine, The Brain Research Institute, and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America, Department of Molecular and Medical Pharmacology, The Brain Research Institute, and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯